You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):擬用於神經阻滯術後鎮痛的注射用HR18034獲批開展臨牀試驗
格隆匯 05-19 16:59

格隆匯5月19日丨恆瑞醫藥(600276.SH)公佈,近日,公司子公司上海恆瑞醫藥有限公司收到國家藥品監督管理局(“國家藥監局”)核准簽發關於注射用HR18034的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。

注射用HR18034為長效局部麻醉藥物,擬用於神經阻滯術後鎮痛。常規術後鎮痛的連續給藥需要特殊的裝置和訓練有素的醫護人員,並且容易誘發感染、脊椎血腫等併發症。為此,公司開發了術後鎮痛新型長效藥物——注射用HR18034,以期在患者術後數日維持鎮痛藥效,進而降低臨牀給藥頻率,進一步降低毒性風險、延長有效鎮痛時間並且減少患者的阿片類止痛藥物使用量。經查詢,目前國內外尚無針對該適應症的同類產品獲批上市,亦無相關銷售數據。截至目前,注射用HR18034相關項目累計已投入研發費用約3823萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account